drugset / Trial / NCT07031713
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
Phase 1
Recruiting
12 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CARsgen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
A clinical study to explore the safety, efficacy and cell metabolic kinetics of universal CD19/20 car-t cell injection in moderate to severe refractory systemic lupus erythematosus. This study is a single arm, open, exploratory dose increasing clinical study, which aims to evaluate the safety, efficacy and cell metabolic dynamics of ct1192 cells in patients with SLE.
Timeline
- Start
- 2025-07-11
- Primary completion
- 2026-12-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT1192 | Cell therapy | 3e+08 cells | Other |
| Subject | CT1192 | Cell therapy | 4.5e+08 cells | Other |
| Subject | CT1192 | Cell therapy | 6e+08 cells | Other |